Impact of Thyroid Metabolism on the Course of INR Levels in a Patient with Systemic Anticoagulation Suffering from Amiodarone-Induced Thyrotoxicosis

 

 Buy Article Permissions and Reprints

Abstract

We report the case of a 60 year old female patient on continuous systemic anticoagulation therapy with coumarin due to mechanical aortic valve replacement and a more than 3 years lasting amiodarone therapy due to severe ventricular extrasystoles suffering from amiodarone induced thyrotoxicosis (AIT). During the course of AIT, showing different thyroid metabolic conditions, INR levels revealed a course closely related to the thyroid conditions indicating a significant and clear-cut effect of both hyper- and hypothyroidism on systemic anticoagulation therapy with coumarin. This continuous interaction of different thyroid metabolic conditions and the anticoagulation state could be well documented in the presented case over a time period of approximately five months.

References

• 1 Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range.  Chest. 2001;  119 8S-21S
  CrossrefPubMedGoogle Scholar
• 2 Chute JP, Ryan CP, Sladek G, Shakir KM. Exacerbation of warfarin-induced anticoagulation by hyperthyroidism.  Endocr Pract. 1997;  3 77-79
  PubMedGoogle Scholar
• 3 Self TH, Straughn AB, Weisburst MR. Effect of hyperthyroidism on hypoprothrombinemic response to warfarin.  Am J Hosp Pharm. 1976;  33 387-389
  PubMedGoogle Scholar
• 4 Kurnik D, Loebstein R, Farfel Z, Ezra D, Halkin H, Olchovsky D. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland.  Medicine. 2004;  83 107-113
  CrossrefPubMedGoogle Scholar
• 5 Dykin D. Warfarin therapy.  N Engl J Med. 1970;  283 801-803
  PubMedGoogle Scholar
• 6 Bucerius J, Joe AY, Palmedo H, Reinhardt MJ, Biersack HJ. Impact of hypothyroidism on systemic anticoagulation in patients with thyroid cancer and coumarin therapy.  Thyroid. 2006;  16 369-374
  CrossrefPubMedGoogle Scholar
• 7 Kellett HA, Sawers JS, Boulton FE, Cholerton S, Park BK, Toft AD. Problems of anticoagulation with warfarin in hyperthyroidism.  Q J Med. 1986;  58 43-51
  PubMedGoogle Scholar
• 8 Woeber KA, Warner I. Potentiation of warfarin sodium by amiodarone-induced thyrotoxicosis.  West J Med. 1999;  170 49-51
  PubMedGoogle Scholar
• 9 Rice AJ, MacIntosh TJ, Fouts JR, Brunk SF, Wilson WR. Decreased sensitivity to warfarin in patients with myxedema.  Am J Med Sci. 1971;  262 211-215
  PubMedGoogle Scholar
• 10 Sanoski CA, Baumann JL. Clinical observation with the amiodarone / warfarin interaction.  Chest. 2002;  121 19-23
  CrossrefPubMedGoogle Scholar
• 11 Demirkan K, Stephens MA, Newman KP, Self TH. Response to warfarin and other oral anticoagulants. Effect of disease states.  South Med J. 2000;  93 448-455
  PubMedGoogle Scholar
• 12 Kerin NZ, Blevins RD, Goldman LK, Rubenfire M. The incidence, magnitude, and time course of the amiodarone-warfarin interaction.  Arch Intern Med. 1988;  148 1779-1781
  CrossrefPubMedGoogle Scholar
• 13 Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin.  Pharmacol Ther. 1997;  73 67-74
  CrossrefPubMedGoogle Scholar
• 14 Loelinger EA, Esch B van der, Mattern MJ, Hemker HC. The biological disappearance rate of prothrombin, factors VII, IX, and X from plasma in hypothyroidism, hyperthyroidism and during fever.  Thrombosis Diath Haemorrh. 1964;  10 267-277
  PubMedGoogle Scholar
• 15 Wintraub M, Breckenridge RT, Griner PF. The effects of dextrothyroxine on the kinetics of prothrombin activity: Proposed mechanism of the potentiation of warfarin by D-thyroxine.  J Lab Clin Med. 1973;  81 273-279
  PubMedGoogle Scholar

Correspondence

J. BuceriusMD 

Department of Nuclear Medicine

University of Bonn

Sigmund-Freud-Str. 25

53105 Bonn

Germany

Phone: +49/228/287 151 81

Fax: +49/228/287 190 96

Email: jan.bucerius@ukb.uni-bonn.de